Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Toxic Nodular Goiter Workup

  • Author: Anu Bhalla Davis, MD; Chief Editor: George T Griffing, MD  more...
 
Updated: Jul 03, 2013
 

Laboratory Studies

Thyroid function tests[7] - Evidence of hyperthyroidism must be present in order to consider a diagnosis of toxic nodular goiter (TNG). (See image below.)

Patchy uptake of iodine (123I) in a toxic multinodPatchy uptake of iodine (123I) in a toxic multinodular goiter.

See the list below:

  • Third-generation TSH assays are generally the best initial screening tool for hyperthyroidism. Patients with TNG will have suppressed TSH levels.
  • Free T4 levels or surrogates of free T4 levels (ie, free T4 index) may be elevated or within the reference range. An isolated increase in T4 is observed in iodine-induced hyperthyroidism or in the presence of agents that reduce peripheral conversion of T4 to triiodothyronine (T3) (eg, propranolol, corticosteroids, radiocontrast agents, amiodarone).
  • Some patients may have normal free T4 levels (or free T4 index) with an elevated T3 level (T3 toxicosis); this may occur in 5-46% of patients with toxic nodules. Note that the total T3 and T4 levels may often be within the reference range but may be higher than the normal range for a particular individual; this is especially true in patients with nonthyroidal illness in which T3 levels are decreased.

Subclinical hyperthyroidism - Some patients may have suppressed TSH levels with normal free T4 and total T3 levels.

Next

Imaging Studies

Nuclear scintigraphy[7]

  • Nuclear scans should be performed on patients with biochemical hyperthyroidism. Nuclear medicine scans can be performed with radioactive iodine-123 (123 I) or with technetium-99m (99m Tc). These isotopes are chosen for their shorter half-life and because they provide lower radiation exposure to the patient when compared with sodium iodide-131 (Na131 I).
  • 99m Tc is trapped in the thyroid but is not organified. Although convenient,99m Tc scanning may provide misleading results. Some nodules that appear hot or warm on99m TC scan results may be cold on123 I scan results. Nodules with discordant99m Tc and123 I scan results may be malignant; therefore,123 I scanning is preferred.
  • Nuclear scans allow determination of the cause of hyperthyroidism. Patients with Graves disease usually have homogeneous diffuse uptake. Glands with thyroiditis have low uptake.
  • In patients with toxic nodular goiter (TNG), the scan results usually reveal patchy uptake, with areas of increased and decreased uptake. The uptake rate of radioiodine in 24 hours averages approximately 20-30%. Radioactive Na131 I ablation of the thyroid gland may be considered if the thyroid uptake value is elevated. Several therapeutic modalities have been suggested to increase uptake (eg, low iodine diet, lithium, recombinant TSH, propylthiouracil [PTU]).
  • Thyroid scanning is also useful for helping to determine the presence of substernal extension of the thyroid gland, which may contain toxic nodules.

Ultrasonography[7]

  • Ultrasonography is a highly sensitive procedure for delineating discrete nodules that are not palpable during thyroid examination. Ultrasonography is helpful when correlated with nuclear scans to determine the functionality of nodules.
  • Dominant cold nodules should be considered for fine-needle aspiration biopsy prior to definitive treatment of a TNG.
  • This technique may be used to serially examine the size of thyroid nodules.

Other imaging modalities

  • In the workup of patients with compressive or obstructive symptoms, computed tomography (CT) scanning of the neck may help to establish whether the trachea is patent and if tracheal deviation or the impingement of other structures is caused by a nodular goiter.
  • Multinodular goiters, especially those with a substernal component, are often incidental findings on chest radiographs, CT scans, or magnetic resonance imaging (MRI) scans. CT scans with iodinated contrast may induce thyrotoxicosis in individuals with an underlying nontoxic, multinodular goiter by supplying an iodine load (Jod-Basedow effect). This type of thyrotoxicosis is self-limited but may last longer if areas of autonomy already exist within the goiter.
Previous
Next

Procedures

Fine-needle aspiration

  • Fine-needle aspiration is not usually indicated in an autonomously functioning (ie, hot) thyroid nodule. The risk of malignancy is quite low. Interpretation of the cytology specimen is difficult, because it is likely to demonstrate a follicular neoplasm (ie, sheets of follicular cells with little or no colloid), and distinguishing between a benign lesion and a malignant lesion is not possible without histologic sectioning to examine for the presence of vascular or capsular invasion.[8]
  • Perform a fine-needle aspiration biopsy if a dominant cold nodule is present in a multinodular goiter. A clinically significant nodule is larger than 1 cm in maximum diameter, based on either palpation or ultrasonographic images, unless there is an increased risk of malignancy. Nonpalpable nodules may be biopsied with the assistance of ultrasonography.
  • A history of head or neck irradiation during childhood increases the risk of malignancy. Head or neck irradiation in an adult increases the frequency of toxic nodular goiter and of carcinoma of the thyroid. Patients from iodine-replete areas have the same risk of malignancy as persons from iodine-deficient areas.
Previous
Next

Histologic Findings

Autonomous nodules may be monoclonal or polyclonal. Many nodules studied in multinodular goiters may actually be monoclonal, even in the setting of histologically marked phenotypic variation.

The histologic appearance of a multinodular goiter can be highly variable and may involve the presence of normal-sized follicles, microfollicles, or macrofollicles, all coexisting within the same gland. Early goiters display micronodular growth patterns. Actively proliferating follicular cells can be observed within some thyroid follicles, resulting in budding intraluminal projections, while other cells within the same follicle appear to be in the resting phase. Conversely, some follicles show a more uniform appearance of cells. Periods of alternating active and quiescent growth appear to occur within the goiter. Areas of fresh and old hemorrhage with calcification are also occasionally present.

Previous
 
 
Contributor Information and Disclosures
Author

Anu Bhalla Davis, MD Assistant Professor, Department of Internal Medicine, Division of Diabetes, Endocrinology, and Metabolism, University of Texas Medical School at Houston

Disclosure: Nothing to disclose.

Coauthor(s)

Philip R Orlander, MD Director and Professor, Division of Endocrinology, Assistant Dean for Educational Programs, Vice-Chair of Medicine for Education, Program Director, Internal Medicine Residency Program, University of Texas Health Science Center at Houston

Philip R Orlander, MD is a member of the following medical societies: American Association of Clinical Endocrinologists, American Diabetes Association, Endocrine Society, Texas Medical Association

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Kent Wehmeier, MD Professor, Department of Internal Medicine, Division of Endocrinology, Diabetes, and Metabolism, St Louis University School of Medicine

Kent Wehmeier, MD is a member of the following medical societies: American Society of Hypertension, Endocrine Society, International Society for Clinical Densitometry

Disclosure: Nothing to disclose.

Chief Editor

George T Griffing, MD Professor Emeritus of Medicine, St Louis University School of Medicine

George T Griffing, MD is a member of the following medical societies: American Association for the Advancement of Science, International Society for Clinical Densitometry, Southern Society for Clinical Investigation, American College of Medical Practice Executives, American Association for Physician Leadership, American College of Physicians, American Diabetes Association, American Federation for Medical Research, American Heart Association, Central Society for Clinical and Translational Research, Endocrine Society

Disclosure: Nothing to disclose.

Acknowledgements

Robert A Gabbay, MD, PhD Associate Professor of Medicine, Division of Endocrinology, Diabetes and Metabolism, Laurence M Demers Career Development Professor, Penn State College of Medicine; Director, Diabetes Program, Penn State Milton S Hershey Medical Center; Executive Director, Penn State Institute for Diabetes and Obesity

Robert A Gabbay, MD, PhD is a member of the following medical societies: American Association of Clinical Endocrinologists, American Diabetes Association, and Endocrine Society

Disclosure: Novo Nordisk Honoraria Speaking and teaching; Merck Honoraria Speaking and teaching

Asra Kermani, MBBS Postdoctoral Fellow, Center for Human Nutrition, University of Texas Southwestern Medical School

Asra Kermani, MBBS is a member of the following medical societies: American College of Physicians-American Society of Internal Medicine

Disclosure: Nothing to disclose.

References
  1. Lado-Abeal J, Palos-Paz F, Perez-Guerra O, et al. Prevalence of mutations in TSHR, GNAS, PRKAR1A and RAS genes in a large series of toxic thyroid adenomas from Galicia, an iodine deficient area in NW Spain. Eur J Endocrinol. 2008 Aug 11. [Medline].

  2. Abraham-Nordling M, Törring O, Lantz M, et al. Incidence of hyperthyroidism in Stockholm, Sweden, 2003-2005. Eur J Endocrinol. 2008 Jun. 158(6):823-7. [Medline].

  3. Brandt F, Thvilum M, Almind D, Christensen K, Green A, Hegedüs L, et al. Graves' disease and toxic nodular goiter are both associated with increased mortality but differ with respect to the cause of death: a Danish population-based register study. Thyroid. 2013 Apr. 23(4):408-13. [Medline].

  4. Basaria S, Salvatori R. Images in clinical medicine. Pemberton's sign. N Engl J Med. 2004 Mar 25. 350(13):1338. [Medline].

  5. Gabriel EM, Bergert ER, Grant CS, et al. Germline polymorphism of codon 727 of human thyroid-stimulating hormone receptor is associated with toxic multinodular goiter. J Clin Endocrinol Metab. 1999 Sep. 84(9):3328-35. [Medline]. [Full Text].

  6. Muhlberg T, Herrmann K, Joba W, et al. Lack of association of nonautoimmune hyperfunctioning thyroid disorders and a germline polymorphism of codon 727 of the human thyrotropin receptor in a European Caucasian population. J Clin Endocrinol Metab. 2000 Aug. 85(8):2640-3. [Medline]. [Full Text].

  7. American Association of Clinical Endocrinologists and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules. Endocr Pract. 2006 Jan-Feb. 12(1):63-102. [Medline].

  8. Cerci C, Cerci SS, Eroglu E, et al. Thyroid cancer in toxic and non-toxic multinodular goiter. J Postgrad Med. 2007 Jul-Sep. 53(3):157-60. [Medline].

  9. van Soestbergen MJ, van der Vijver JC, Graafland AD. Recurrence of hyperthyroidism in multinodular goiter after long-term drug therapy: a comparison with Graves' disease. J Endocrinol Invest. 1992 Dec. 15(11):797-800. [Medline].

  10. Bahn Chair RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid. 2011 Jun. 21(6):593-646. [Medline].

  11. Allahabadia A, Daykin J, Sheppard MC, et al. Radioiodine treatment of hyperthyroidism-prognostic factors for outcome. J Clin Endocrinol Metab. 2001 Aug. 86(8):3611-7. [Medline]. [Full Text].

  12. Zingrillo M, Urbano N, Suriano V, et al. Radioiodine treatment of Plummer and multinodular toxic and nontoxic goiter disease by the first approximation dosimetry method. Cancer Biother Radiopharm. 2007 Apr. 22(2):256-60. [Medline].

  13. Erkan ME, Demirin H, Asik M, Celbek G, Yildirim M, Aydin Y, et al. Efficiency of radioactive I-131 therapy in geriatric patients with toxic nodular goiter. Aging Clin Exp Res. 2012 Dec. 24(6):714-7. [Medline].

  14. Albino CC, Mesa CO Jr, Olandoski M, et al. Recombinant human thyrotropin as adjuvant in the treatment of multinodular goiters with radioiodine. J Clin Endocrinol Metab. 2005 May. 90(5):2775-80. [Medline].

  15. Duick DS, Baskin HJ. Utility of recombinant human thyrotropin for augmentation of radioiodine uptake and treatment of nontoxic and toxic multinodular goiters. Endocr Pract. 2003 May-Jun. 9(3):204-9. [Medline].

  16. Adamali HI, Gibney J, O'Shea D, et al. The occurrence of hypothyroidism following radioactive iodine treatment of toxic nodular goiter is related to the TSH level. Ir J Med Sci. 2007 Sep. 176(3):199-203. [Medline].

  17. Bonnema SJ, Bertelsen H, Mortensen J, et al. The feasibility of high dose iodine 131 treatment as an alternative to surgery in patients with a very large goiter: effect on thyroid function and size and pulmonary function. J Clin Endocrinol Metab. 1999 Oct. 84(10):3636-41. [Medline].

  18. FDA MedWatch Safety Alerts for Human Medical Products. Propylthiouracil (PTU). US Food and Drug Administration. Accessed: June 3, 2009. Available at http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm164162.htm.

  19. Smith JJ, Chen X, Schneider DF, Nookala R, Broome JT, Sippel RS, et al. Toxic nodular goiter and cancer: a compelling case for thyroidectomy. Ann Surg Oncol. 2013 Apr. 20(4):1336-40. [Medline].

  20. Bonnema SJ, Bennedbaek FN, Veje A, et al. Propylthiouracil before 131I therapy of hyperthyroid diseases: effect on cure rate evaluated by a randomized clinical trial. J Clin Endocrinol Metab. 2004 Sep. 89(9):4439-44. [Medline]. [Full Text].

  21. Azizi F, Khoshniat M, Bahrainian M, et al. Thyroid function and intellectual development of infants nursed by mothers taking methimazole. J Clin Endocrinol Metab. 2000 Sep. 85(9):3233-8. [Medline]. [Full Text].

  22. Momotani N, Yamashita R, Makino F, et al. Thyroid function in wholly breast-feeding infants whose mothers take high doses of propylthiouracil. Clin Endocrinol (Oxf). 2000 Aug. 53(2):177-81. [Medline].

  23. Aeschimann S, Kopp PA, Kimura ET, et al. Morphological and functional polymorphism within clonal thyroid nodules. J Clin Endocrinol Metab. 1993 Sep. 77(3):846-51. [Medline]. [Full Text].

  24. Aghini-Lombardi F, Antonangeli L, Martino E, et al. The spectrum of thyroid disorders in an iodine-deficient community: the Pescopagano survey. J Clin Endocrinol Metab. 1999 Feb. 84(2):561-6. [Medline]. [Full Text].

  25. Clark KJ, Cronan JJ, Scola FH. Color Doppler sonography: anatomic and physiologic assessment of the thyroid. J Clin Ultrasound. 1995 May. 23(4):215-23. [Medline].

  26. Cooper DS. Hyperthyroidism. Lancet. 2003 Aug 9. 362(9382):459-68. [Medline].

  27. Dumont JE, Lamy F, Roger P, et al. Physiological and pathological regulation of thyroid cell proliferation and differentiation by thyrotropin and other factors. Physiol Rev. 1992 Jul. 72(3):667-97. [Medline].

  28. Erem C, Kandemir N, Hacihasanoglu A, et al. Radioiodine treatment of hyperthyroidism: prognostic factors affecting outcome. Endocrine. 2004 Oct. 25(1):55-60. [Medline].

  29. Erickson D, Gharib H, Li H, et al. Treatment of patients with toxic multinodular goiter. Thyroid. 1998 Apr. 8(4):277-82. [Medline].

  30. Feit H. Thyroid function in the elderly. Clin Geriatr Med. 1988 Feb. 4(1):151-61. [Medline].

  31. Grubeck-Loebenstein B, Buchan G, Sadeghi R, et al. Transforming growth factor beta regulates thyroid growth. Role in the pathogenesis of nontoxic goiter. J Clin Invest. 1989 Mar. 83(3):764-70. [Medline]. [Full Text].

  32. Holzapfel HP, Fuhrer D, Wonerow P, et al. Identification of constitutively activating somatic thyrotropin receptor mutations in a subset of toxic multinodular goiters. J Clin Endocrinol Metab. 1997 Dec. 82(12):4229-33. [Medline]. [Full Text].

  33. Kang AS, Grant CS, Thompson GB, et al. Current treatment of nodular goiter with hyperthyroidism (Plummer's disease): surgery versus radioiodine. Surgery. 2002 Dec. 132(6):916-23; discussion 923. [Medline].

  34. Koornstra JJ, Kerstens MN, Hoving J, et al. Clinical and biochemical changes following 131I therapy for hyperthyroidism in patients not pretreated with antithyroid drugs. Neth J Med. 1999 Nov. 55(5):215-21. [Medline].

  35. Kraiem Z, Glaser B, Yigla M, et al. Toxic multinodular goiter: a variant of autoimmune hyperthyroidism. J Clin Endocrinol Metab. 1987 Oct. 65(4):659-64. [Medline].

  36. Krohn K, Paschke R. Clinical review 133: progress in understanding the etiology of thyroid autonomy. J Clin Endocrinol Metab. 2001 Jul. 86(7):3336-45. [Medline]. [Full Text].

  37. Lavard L, Sehested A, Brock Jacobsen B, et al. Long-term follow-up of an infant with thyrotoxicosis due to germline mutation of the TSH receptor gene (Met453Thr). Horm Res. 1999. 51(1):43-6. [Medline].

  38. Maussier ML, D'Errico G, Putignano P, et al. Thyrotoxicosis: clinical and laboratory assessment. Rays. 1999 Apr-Jun. 24(2):263-72. [Medline].

  39. Pearce EN, Braverman LE. Hyperthyroidism: advantages and disadvantages of medical therapy. Surg Clin North Am. 2004 Jun. 84(3):833-47. [Medline].

  40. Reiners C, Schneider P. Radioiodine therapy of thyroid autonomy. Eur J Nucl Med Mol Imaging. 2002 Aug. 29 Suppl 2:S471-8. [Medline].

  41. Sato K, Miyakawa M, Eto M, et al. Clinical characteristics of amiodarone-induced thyrotoxicosis and hypothyroidism in Japan. Endocr J. 1999 Jun. 46(3):443-51. [Medline].

  42. Siegel RD, Lee SL. Toxic nodular goiter. Toxic adenoma and toxic multinodular goiter. Endocrinol Metab Clin North Am. 1998 Mar. 27(1):151-68. [Medline].

  43. Talbot JN, Duron F, Piketty ML, et al. Low thyrotropin (TSH) levels in goiter. Relationship with scintigraphic findings and other biological parameters. Thyroidology. 1989 Apr. 1(1):39-44. [Medline].

  44. Tonacchera M, Chiovato L, Pinchera A, et al. Hyperfunctioning thyroid nodules in toxic multinodular goiter share activating thyrotropin receptor mutations with solitary toxic adenoma. J Clin Endocrinol Metab. 1998 Feb. 83(2):492-8. [Medline]. [Full Text].

  45. Tonacchera M, Vitti P, Agretti P, et al. Activating thyrotropin receptor mutations in histologically heterogeneous hyperfunctioning nodules of multinodular goiter. Thyroid. 1998 Jul. 8(7):559-64. [Medline].

Previous
Next
 
Patchy uptake of iodine (123I) in a toxic multinodular goiter.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.